Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial (Q43212287)
Jump to navigation
Jump to search
scientific article published on 21 December 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial |
scientific article published on 21 December 2009 |
Statements
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response (English)
Nan Soon Wong
Robert A Buckman
Shailendra Verma
Susan Dent
Maureen E Trudeau
Kathie Roche
Robert Kerbel
Gerrit E Deboer
Donald J A Sutherland
Urban Emmenegger
Joyce Slingerland
Sandra Gardner
21 December 2009